#CannabisExtraction #Stocks in the News (CSE: $XTRX.C) (TSX-V: $RTI.V) (TSX: $VLNS.TO) (CSE: $OILS.C) @adastra_labs @RadientInc @TheValensCo @nextleaf_oils
Point
Roberts WA, Delta, BC –April 29, 2021 - Investorideas.com, a leading
investor news resource covering cannabis and hemp stocks releases a special
report on the accelerated growth within the extracts and “Cannabis 2.0”
categories as more companies further distribution and expand R&D
capabilities, featuring Phyto
Extractions Inc. (formerly Adastra
Labs Holdings Ltd.) (CSE:XTRX).
Read this article,
featuring XTRX in full at https://www.investorideas.com/news/2021/cannabis/04291Cannabis-Extraction-Stocks.asp
The global cannabis extract market size was
valued at USD 7.3 billion in 2019 and is anticipated to register a CAGR of
16.6% over the forecast period to 2027 says Grandview Research.
One company set to capitalize on this
extract growth is Phyto Extractions Inc. (formerly Adastra Labs Holdings Ltd.)
(CSE:XTRX). Phyto
Extractions™ is an agricultural-scale cannabis extraction, distillation and
product manufacturer located in Langley, BC at its co-located Health Canada
Licensed Standard Processing (extraction and products, no cultivation), Sales
(extracts, topicals and edibles) and R&D through Adastra Labs Inc. and
Analytical Testing Laboratory through Chemia Analytics Inc.
According to Phyto Extractions
news,
“The current cannabis extract market has seen a huge boom in sales from the
past year, in which demands for cannabis extracts are rising steadily. Canadian
cannabis extract sales observed an exponential 315% growth rate for the past
two years, from 320,201 non-medical sales in Oct. 2019 to 1,328,769 sales in
Oct. 2020, and over 200% sales growth rate including all medical and
non-medical sales. Rising demand for cannabis extract products requires
reasonable supplies from producers for cannabis enthusiasts.”
The Company recently announced that it has
received its Health Canada R&D license addendum in Adastra Labs Inc. that
will permit some limited human testing by licensed researchers administering or
distributing cannabis to human research subjects using cannabis obtained from a
holder of a license for processing in the final form of cannabis.
This R&D license addendum will permit
the Company to conduct in-house human testing for taste of various cannabis
products for assessment of taste, sights, smell, or touch of cannabis.
"We look forward to initiating
human-studies and generating valuable consumer-based data to support our
product development pipeline and continue delivering high-quality efficacious
cannabis products to Canadians," stated Dr. Kyle Boniface, PhD.
The Company also announced
on April 21st they are now
producing cannabis shatter products for the Canadian market after wholly-owned
subsidiary Adastra Labs Inc.'s commissioning of new hydrocarbon extraction
equipment ahead of schedule.
From
the news: “With the arrival of the ExtractionTek
Solutions MeP XT70 system, a high-performance hydrocarbon extractor, the team
at Phyto Extractions can now process over 400 KG per day of cannabis biomass
into a variety of hydrocarbon cannabis concentrate products. Focused on shatter
production currently, this translates into over 50kg of high-quality product
output per day.”
From
the news: “Phyto Extractions™ has launched three new
shatter cannabis products: Pink Kush, Blue Gorilla OG, and D. Bubba that will
serve the over 9 million Canadians currently in the cannabis market with its
one-gram offerings. The Company's increasing market share in the disposable
vape, vape cartridge, and live resin markets, strengthens the brand's launch of
its new flagship 'shatter' product line.”
From
the news: “With relatively few players in the niche of
shatter product space in Canada, this market expansion represents a significant
opportunity given the forecasted growth of the Cannabis extract market.”
Shatter
video: https://youtu.be/Bo4VWLSAT7o
Radient
Technologies Inc. (TSX-V:
RTI)
(OTCQX:
RDDTF),
a cannabis company utilizing a
proprietary extraction and downstream processing platform, in December 2020 announced its licensing
agreement with Tunaaaaroom to manufacture and distribute a wide range of
premium cannabis extracts targeting recreational cannabis consumers in Canada.
Radient will make use of its Health Canada Cannabis Research and Analytical
Testing licenses to fully characterize the Tunaaaa strains and evaluate the
sensory qualities of extracts formulated to mimic the specific terpene profiles
and containing differing cannabinoid profiles and potencies.
Based in Edmonton, Tunaaaa has spent over
six years developing the genetics for over 1,000 high-quality cannabis strains
containing proprietary terpene profiles. Through this licensing deal, Radient
will gain access to Tunaaaa’s specific genetics and will engage the Tunaaaa
breeders as consultants to help drive product development.
Radient will further make use of its
Standard Processing and Sales Licenses to rapidly launch premium distillate dab
and vape extracts. Radient plans to bring Tunaaaa’s vast catalogue of unique
flavours to the market with monthly drops of new terp profiles. Radient and
Tunaaaa will also work in collaboration on CBD and CBN distillate dabs to
create additional unique terpene extract products for recreational cannabis consumers.
Future Radient extract products may include
Cannabis 2.0 products like diamond, shatter, caviars, live rosin, terp sauce as
well as micro cannabinoid isolates and edibles.
The
Valens Company Inc.
(TSX:
VLNS)
(OTCQX:
VLNCF),
a leading manufacturer of cannabis products, specifically in the Cannabis 2.0
product category recently
announced
expansion of its distribution in both Manitoba and the Yukon, having entered
into an agreement with the Manitoba Liquor & Lotteries Corporation to supply
and distribute a wide range of cannabis products to LGCA-licensed private
retailers in the Province of Manitoba, as well as its entry into the Yukon
market with a cannabis purchase and sale agreement with the Yukon Liquor
Corporation (YLC). With this agreement, Valens expands its distribution network
to five provinces in the country.
"Expanding our domestic distribution
capabilities is one of our top strategic initiatives to drive growth this year
and beyond," said Tyler Robson, Chief Executive Officer, Co-Founder and
Chair of The Valens Company. "Our entry into the Manitoba market takes us
a step further toward capturing larger market share and bringing the Valens
advantage to consumers in a new province, enabling greater access to our
high-quality products across Canada."
"Our entry into the Yukon market not
only furthers our ability to capture market share in Canada, but also broadens
the selection and quality of products that consumers in the territory can
access," continued Tyler Robson. "We have made significant progress
growing our cannabis distribution network and we expect to increase our
national position in the short-term as we continue discussions with other
private and government-regulated retailers across the country."
Valens has already shipped several products
to the province, including A1 Cannabis' Summit 10 THC beverages, Verse
Cannabis' Tropic Lemon and Sunset Peach vape carts and 1:20 CBD oil, with
additional product formats across various categories expected to be shipped in
the coming weeks.
Nextleaf
Solutions Ltd.
(CSE:
OILS)
(OTCQB:
OILFF),
the world's most innovative cannabis processor, announced in March, 2021
that it has commenced human trials of cannabis vapes.
Under its amended Cannabis Research Licence
from Health Canada, Nextleaf is collecting sensory evaluation data from
qualified volunteers completing organoleptic assessments of a wide variety of
formulated cannabis vape products. The Company is comprehensively testing a
range of cannabinoid and terpene formulations, including how various vape
hardware interacts with different formulations. Nextleaf expects to accelerate
product development and drastically shorten design cycles for launching new
cannabis vape products by validating formulations and delivery technologies
more efficiently.
Forbes wrote a feature around Nextleaf's
human trial program on March 30, 2021 and the article can
be read here.
"The amended Cannabis Research Licence
allows Nextleaf to rapidly formulate a wide variety of cannabis products and
administer samples to volunteer research participants," said Nextleaf
Solutions R&D Lead, Dr. David Novitski. "The ability to provide
commercial partners with data-based consumer insights around taste and overall
user experience is a true game changer for product development."
Since becoming legal in Canada, vapes have
emerged as the clear leader of all cannabis 2.0 products. According to the most
recent data from the Ontario Cannabis Store, the vape category ranks second
only to dried flower with 15.7% of all Ontario cannabis sales. In more mature
adult-use markets like Colorado, Oregon, and Washington, the market share for
cannabis vapes reached as high as 22.3%, according to data from Headset. As
Canada continues to roll out brick and mortar cannabis retail stores, the vape
segment is expected to continue to increase in overall size and market share.
The Company believes the CBD vape subcategory could see significant growth
should Health Canada regulations change to allow for increased legal access to
CBD products. Nextleaf plans to validate its proprietary CBD vape technology
under its amended Cannabis Research Licence.
Collecting data-based consumer insights is
particularly important in an increasingly competitive market in which initial
product launches can dictate the long-term success of a brand.
"There are a lot of subpar vape
products available in the market today that have not gone through rigorous
testing and human trials," said Nextleaf Solutions CEO Paul Pedersen.
"Issues such as poor taste, clogging, leaking, and crystallization in CBD
vapes are well documented throughout the industry. Collecting consumer feedback
during product development is key to launching differentiated cannabis 2.0
products that provide consumers with a positive experience and value."
Considering the recent cannabis investments
by large pharmaceutical and tobacco companies, it is apparent that generating
and protecting intellectual property is becoming more important in the next
phase of the industry's maturation. Management believes Nextleaf is well
positioned with its product innovation pipeline and success securing issued
patents in the United States. Nextleaf owns 12 US patents and has been issued
over 70 patents globally. Innovation is core to Nextleaf's value proposition,
and its ability to differentiate with its patented and patent pending
cannabinoid delivery technologies and formulations. The amended Cannabis
Research Licence allows Nextleaf to continue to develop, validate, and
strengthen its R&D within a federally legal market.
As we see more extract companies expanding
their R&D and distribution capabilities, we see a three-fold gain to the
industry. This will create accelerated growth and competition in the category,
higher quality products for consumers which will be more effective through
proper research, as well as important industry data points through having
access to proper research techniques which can have a massive benefit to both
the medical and recreational market moving forward.
As both the Canadian and US cannabis
industries begin to enter into a state of maturation and stability we see the
Cannabis 2.0 product category continue to gain a larger sales footing which can
only be expected to grow further as consumer awareness rises along with product
consistency and availability.
About
Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: this
news article featuring XTRX is a paid for news release on
Investorideas.com (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp
Learn more about publishing your news release and our other news services on
the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Contact
Investorideas.com
800-665-0411
Get more Cannabis Stock
Investor Ideas - news, articles, podcasts and
stock directories
No comments:
Post a Comment